Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Thabor Therapeutics Appoints Jérémie Mariau as Ceo
Thabor Therapeutics, a company developing an innovative treatment for patients living with chronic mucosal inflammatory […]
AdBio Partners Welcomes Inserm Transfert As Investor in Second Fund – AFB Fund II
AdBio partners, an AMF-regulated (the French financial market authority) investment company dedicated to life sciences, […]
Univercells Acquires SynHelix, Entering into Synthetic Biology and the Race to Next-generation DNA Synthesis
Univercells S.A. (Univercells) today announces its acquisition of SynHelix, a biotechnology company that aims to debottleneck […]
Advent France Biotechnology Launches its Second Fund with a First Close at €86M ($102M)
Advent France Biotechnology (AFB), an AMF-regulated investment company dedicated to life sciences, today announces the […]
Advent France Biotechnology (AFB) Appoints Sidonie Fabre as CFO
Advent France Biotechnology (AFB), an AMF-regulated investment company dedicated to life sciences, today announces the […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more